EZN-2279

· Leadiant Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EZN-2279, covering 2020-04-16 to 2020-04-16. Get the full timeline:

Most recent: Clinical Trial Update: EZN-2279 in Patients With ADA-SCID [Phase 3]